PharmaMar Victory Has EU Regulators Pondering Next Move
Top EU Court Says Filing For Multiple Myeloma Drug Was Wrongly Rejected
Executive Summary
PharmaMar’s persistence has paid off in its fight to overturn the European Commission’s rejection of its marketing application for the multiple myeloma drug, Aplidin.